Proteolytic pan-RAS Cleavage Leads to Tumor Regression in Patient-derived Pancreatic Cancer Xenografts.

Overview of attention for article published in Molecular Cancer Therapeutics, February 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

So far, Altmetric has seen 23 X posts from 21 X users, with an upper bound of 80,663 followers.

RT @MCT_AACR: Lack of effective RAS inhibition represents a major unmet medical need in pancreatic ductal #adenocarcinoma. Vidimar et al re…

RT @MCT_AACR: Lack of effective RAS inhibition represents a major unmet medical need in pancreatic ductal #adenocarcinoma. Vidimar et al re…

RT @MCT_AACR: Lack of effective RAS inhibition represents a major unmet medical need in pancreatic ductal #adenocarcinoma. Vidimar et al re…

RT @MCT_AACR: Lack of effective RAS inhibition represents a major unmet medical need in pancreatic ductal #adenocarcinoma. Vidimar et al re…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 19 additional X posts.